Table 1.
Number of samples collected through TES from 2016 to 2021 and sequenced for detection of markers of drug resistance
| Year | # Samples sequenced | k13* (%) | pfmdr1-region 1* (%) | pfmdr1-region2* (%) |
|---|---|---|---|---|
| 2016 | 423 | 376 (88.9) | 423 (100.0) | 423 (100.0) |
| 2018 | 426 | 359 (84.0) | 401 (94.0) | 379 (89.0) |
| 2019 | 403 | 353 (88.0) | 371 (91.7) | 372 (92.0) |
| 2020 | 412 | 348 (8.0) | 378 (93.0) | 330 (80.0) |
| 2021 | 351 | 333 (95.0) | 335 (95.0) | 270 (77.0) |
| Total | 2015 | 1769 (87.8) | 1908 (94.7) | 1774 (88.0) |
#Number of samples attempted during sequencing
*number and proportions of samples which passed the sequencing quality score criteria and were therefore used in the analysis